Background: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer,
which is the leading cause of death worldwide with the majority of patients presenting with advanced
disease at the time of diagnosis.
Objective: In this review, the emergence of erlotinib as a seed for the treatment of NSCLC has been
discussed and how it is gaining limelight as one of the most suitable drugs for this indication. The approval
status in different regions and recommendation data from Health Technology Assessment
(HTA) agencies like National Institute for Care and Excellence (NICE), UK and Wales and Scottish
Medical Consortium (SMC), Scotland have also been collected in this study.
Method: For carrying out the review, literature was searched on various databases including PubMed,
Clinicaltrial.gov, various HTA databases, EMBASE, Google Scholar, United States Food and Drugs
Administration (USFDA) and various other online databases. Information from these sources was
compared and analyzed as per the requirement of the objective.
Results: From the literature obtained after searching various databases, it was observed that Erlotinib
(Tarceva) is one of the drugs which acts on EGFR and was approved (2004) from USFDA for treating
locally advanced or metastatic NSCLC, as second or third line treatment after the failure of chemotherapy
regimen. Different Health Technology Assessment (HTA) agencies have also assessed erlotinib
for various indications and have given guidance for its use.
Conclusion: On the basis of available literature and data on clinical studies, it can be concluded that
erlotinib can be the better option for treatment of NSCLC and effective against different lines of
treatment and in maintenance as well.